Thermo Fisher Scientific (TMO) PT Raised to $585 at Cowen

Cowen analyst Doug Schenkel raised the price target on Thermo Fisher Scientific (NYSE: TMO) to $585.00 (from $525.00) while maintaining an Outperform rating.

The analyst commented, "COVID-19 drove another revenue & EPS beat in Q4. Encouragingly, the base business returned to ~MSD growth. 2021 guidance is above expectations and appears to leave room for upside. Importantly, TMO continues to invest and execute pristinely from a position of strength. We have high conviction that this management team can navigate through upcoming challenging comparisons. Reiterate Outperform."

You May Also Be Interested In

• Travelers (TRV) PT Raised to $163 at RBC Capital As Record Catastrophe Losses Offset by Margins and Reserves
• Edwards Lifesciences (EW) PT Raised to $103 at Stifel
• Johnson & Johnson (JNJ) PT Raised to $204 as Goldman Sachs Sees S&P Discount Unwarranted